Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Pulse Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Pulse Biosciences, Inc.

PLSE

Pulse Biosciences, Inc.

About Pulse Biosciences, Inc.

Pulse Biosciences develops nonthermal ablation devices utilizing patented Nano-pulse Stimulation (NPS) technology for medical applications in dermatology, cardiology, and soft tissue treatment. Its core product, the CellFX System, and related platforms aim to improve outcomes by precisely targeting cells while sparing surrounding tissue. The company focuses on innovative, minimally invasive therapies for conditions like benign skin lesions and atrial fibrillation, emphasizing safety, efficacy, and regulatory approval.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Pulse Biosciences, Inc.

1
1
Pulse Biosciences, Inc. Pulse Biosciences Reports First Revenue of $401,000 and Increased Net Loss in Q1 2026

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Pulse Biosciences, Inc. Pulse Biosciences Reports $350,000 in Product Revenue for Fiscal Year 2025 Amid Increased Losses

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Pulse Biosciences, Inc. Pulse Biosciences Reports First Revenue of $86,000 in Q3 2025 Amid Increased Losses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Pulse Biosciences, Inc. Pulse Biosciences Reports $19.2 Million Net Loss and No Revenue in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Pulse Biosciences, Inc. Pulse Biosciences Reports $16.8 Million Net Loss in Q1 2025, No Revenue Generated

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Pulse Biosciences, Inc. Pulse Biosciences Reports $53.6 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Pulse Biosciences, Inc. Pulse Biosciences Reports Increased Cash Reserves, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments